NICE asks for more data on rimonabant
NICE has ruled against the use of the anti-obesity drug rimonabant in a preliminary recommendation.
The institute has asked the manufacturer Sanofi Aventis for more data on cardiovascular risk outcomes in patients who have successfully lost weight while taking the drug.
The institute has also asked for clearer cost efficacy data comparing the drug to orlistat, sibutramine and diet and exercise.
Rimonabant is an endo-cannibinoid blocker which it acts centrally and peripherally to increase the sensation of fullness and reduce food intake.
Since its launch a number of studies have suggested higher than expected rates of depression in patients taking the drug.
The closing date for comments on the consultation document is 7th January 2008.